Radiotherapy

Phase 3Small molecule

GSK

Radiotherapy is one of 29 small molecule programs targeting Chemoradiotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemoradiotherapyRecruiting

ChemoradiotherapyPhase 3

Recruiting

Competition

Competitive Landscape

33 competitors in Chemoradiotherapy

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

5 2

Eloxatin

Teva

Phase 3

4 3

Imjudo

AstraZeneca

Phase 3

2 4

Taxol

Teva

Phase 3

2 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

10 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 7

Paraplatin

AAvyxa

Phase 3

3 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 9

Tuoyi

CCoherus Oncology, Inc.

Phase 3

2 10

Alimta

SShawn Eagle

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Chemoradiotherapy

NCT05674305

Clinical

Trials by Indication[1]

Astrocytoma1 trial

Radiotherapy for Malignant Astrocytomas in the Elderly

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00430911

Head and Neck Cancer1 trial

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

Completed· GSK logo

GSK·Phase 2·NCT00387127·67 enrolled

Chemoradiotherapy1 trial

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Recruiting·FFudan University·Phase 3·NCT05674305·366 enrolled

Advanced NSCLC1 trial

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03044626·101 enrolled

Lymphoma1 trial

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma

Unknown status·FFudan University·Phase 2·NCT01667302·30 enrolled

2 more indications

Radiation Therapy1 trial

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Unknown status·AAUSL Romagna Rimini·Phase 2·NCT04083365·100 enrolled

TED1 trial

Simultaneous Integrated Boost (SIB)- IMRT

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00389727·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Radiotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radiotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radiotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Radiotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Astrocytoma1 trial

Head and Neck Cancer1 trial

Chemoradiotherapy1 trial

Advanced NSCLC1 trial

Lymphoma1 trial

Radiation Therapy1 trial

TED1 trial

References

Drug Info

Quick Facts

Related News